Figure 3.
CECs possess surface expression of ACE2
(A) Plots showing the expression of ACE2 on CD3 T cells, CD14 monocytes, CD15 neutrophils, CD19 B cells, CD16CD56 NK cells, and CECs in PBMCs from COVID-19 patients compared with the isotype control antibody.
(B and C) (B) Image stream plots showing the expression of ACE2 on CECs, and (C) the co-localization of ACE2 with CD71/CD235a on CECs in PBMCs from COVID-19 patients.
(D) Fold regulation of ACE2 mRNA in CECs and immune cell lineages from PBMCs from six COVID-19 patients, three with moderate and three with severe disease, compared with VeroE6 cells as quantified by qPCR.
(E) Western blot data showing the presence of ACEs protein in a mouse lung tissue, CECs from PBMCs from two COVID-19 patients and CECs (∼1 × 106 cells) isolated from a human placenta.